Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropsychiatric and Synaptic Repair Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CBLN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CBLN1 Recombinant Protein (Human/Mouse) HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. Supports oligomeric assembly studies. |
View CBLN1 Products |
| Gene Delivery | CBLN1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and primary neuron transduction. |
View CBLN1 Products |
| Benchmark Ab | Anti-CBLN1 Recombinant Antibody Recombinant positive control for ELISA, IHC, and binding assays. |
View CBLN1 Products |
| Validator | CBLN1 siRNA Set Target-specific knockdown verification in neuronal co-culture models. |
View CBLN1 Products |
| Related Target A | GRID2 (GluD2) Postsynaptic glutamate receptor delta-2. Direct binding partner of CBLN1, forming the trans-synaptic bridge. |
View GRID2 Products |
| Related Target B | NRXN1 (Neurexin-1) Presynaptic binding partner. Synergistic target for synaptic organizer and repair therapies. |
View NRXN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Oligomeric State Maintenance (Hexameric Assembly) | HEK293 mammalian expression system guarantees correct disulfide-linked oligomerization and native post-translational modifications. |
| Dual-Binding Affinity Assessment (NRXN1 vs. GRID2) | High-purity recombinant orthologs (Human/Mouse) with verified theoretical molecular weights for precise SPR/BLI binding kinetics. |
| Primary Neuron Culture Toxicity | Strict endotoxin control (<1.0 EU/μg) to prevent microglial activation and non-specific neurotoxicity in functional in vitro assays. |
| Lack of Validated Controls | Sequence-verified biosimilar recombinant antibodies and specific siRNA knockdown pools included for target validation. |
Live CBLN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CBLN1 (Cerebellin-1) is emerging as a frontier in neurobiology, driven by its role as a bidirectional synaptic organizer. Rather than traditional monoclonal antibody inhibition, current R&D is focused on engineered synaptic organizers (such as CPTX, a synthetic fusion protein combining the binder domains of CBLN1 and neuronal pentraxin) and gene therapy vectors to restore synaptic connectivity. As first-generation synaptic organizers demonstrate efficacy in spinal cord injury and cerebellar ataxia models, the next wave of R&D is targeting cognitive preservation in Alzheimer's disease and neurodevelopmental disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Engineered Synaptic Organizers (Fusions) | Academic Institutes, Biopharma Consortia | Spinal Cord Injury, Cerebellar Ataxia | Dual-affinity binding assays (Requires highly pure, glycosylated GRID2 and NRXN1 partner proteins) |
| Gene Therapy (AAV-CBLN1) | Neurology-focused Biotech Startups | Alzheimer's Disease, Synaptic Loss | Transduction efficiency and expression validation (Requires sequence-verified mammalian CBLN1 standards) |
| Small Molecule / Peptide mimetics | Neuro-regeneration Developers | Cognitive Decline, Neuropsychiatric Disorders | High-throughput screening of disruptors or stabilizers (Requires stable, endotoxin-free recombinant proteins) |